Yazar "Erul, Enes" için listeleme
-
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Kahraman, Seda; Erul, Enes; Gumusay, Ozge; Guven, Deniz Can; Aksoy, Sercan; Basaran, Gul; Seyyar, Mustafa (Cig Media Group, Lp, 2025)We conducted a multicenter, retrospective cohort study that included 522 patients with HR+/HER2-MBC treated with ribociclib or palbociclib in combination with fulvestrant. Although the three CDK4/6 inhibitors did not seem ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Çakan Demirel, Burçin; Acar, Ömer; Aksoy, Sercan; Kose Baytemur, Naziyet; Şahin, Elif; Çabuk, Devrim; Basaran, Gül; Paydas, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hizal, Mutlu; Gülbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Özlem; Oyuncu Orhan, Sibel; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Eylemer Mocan, Eda; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Oyan Uluc, Başak; Özcelik, Melike; Hacibekiroğlu, İlhan; Aydiner, Adnan; Demir, Hacer; Oksuzoğlu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Bozkurt Duman, Berna; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Barış; İnal, Ali; Iriağac, Yakup; Onal Kalkan, Nurhan; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Özlem; Turhal, Nazim Serdar; Karadurmuş, Nuri; Yalçın, Bulent; Sendur, Mehmet Ali Nahit (Future Medicine Ltd., 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
